Compare MNDR & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MNDR | PPCB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Singapore | Australia |
| Employees | N/A | 2 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 1.9M |
| IPO Year | 2023 | N/A |
| Metric | MNDR | PPCB |
|---|---|---|
| Price | $0.81 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 306.0K | ★ 6.4M |
| Earning Date | 03-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $608,852.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.10 |
| 52 Week High | $5.42 | $10.69 |
| Indicator | MNDR | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 43.03 |
| Support Level | $0.79 | N/A |
| Resistance Level | $1.00 | $0.13 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 40.97 | 12.65 |
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.